[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100398130":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":36,"responsibleParty":71,"collaborators":10,"id":74,"slug":10,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University of Roma La Sapienza","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neuroendocrine toumor group",null,"30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.",[13],"Drug: Somatostatin analog; chemotherapy",{"label":15,"type":10,"description":16,"interventionNames":10},"Control group","Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Somatostatin analog; chemotherapy","According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.",[9],[24],{"name":25,"affiliation":26,"role":27},"Andrea M Isidori, MD, PhD","Department of Experimental Medicine, Sapienza University of Rome","PRINCIPAL_INVESTIGATOR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+390649970540","andrea.isidori@uniroma1.it",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Elisa M Giannetta, MD, PhD","elisa.giannetta@uniroma1.it",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":41,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Andrea M Isidori","RECRUITING","Rome","Italy","00161","IT",{"type":45,"coordinates":46},"Point",[47,48],12.51133,41.89193,{"lat":48,"lon":47},[51,53,54,57,59,61,63,65,67,69],{"name":25,"role":30,"phone":52,"phoneExt":10,"email":32},"00390649970540",{"name":25,"role":27,"phone":10,"phoneExt":10,"email":10},{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Elisa Giannetta, MD, PhD","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":10,"phoneExt":10,"email":10},"Antongiulio Faggiano, MD, PhD",{"name":60,"role":56,"phone":10,"phoneExt":10,"email":10},"Mary Anna Venneri, PhD",{"name":62,"role":56,"phone":10,"phoneExt":10,"email":10},"Maria Grazia Tarsitano, MD, PhD",{"name":64,"role":56,"phone":10,"phoneExt":10,"email":10},"Giulia Puliani, MD",{"name":66,"role":56,"phone":10,"phoneExt":10,"email":10},"Tiziana Feola, MD",{"name":68,"role":56,"phone":10,"phoneExt":10,"email":10},"Franz Sesti, MD",{"name":70,"role":56,"phone":10,"phoneExt":10,"email":10},"Francesca Sciarra, PhD",{"type":27,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Andrea M. Isidori","Full Professor","100398130",false,"NCT04464122","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study","REBORN","Inclusion Criteria:\n\n* Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);\n* Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).\n\nExclusion Criteria:\n\n* Severe chronic kidney disease (stage 4-5);\n* Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;\n* Other non-neuroendocrine malignancies.","ALL","18 Years","80 Years",{"count":85,"type":86},60,"ESTIMATED","OBSERVATIONAL","This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.",[90,91,92,93,94],"Neuroendocrine Tumors","Neuroendocrine Neoplasm","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Carcinoma",[96,97,98,99,100],"Neuroendocrine Tumours","Prognostic markers","Tumour educated platelets","angiogenesis","immune function","2025-03-31",{"date":103,"type":104},"2025-04-03","ACTUAL",{"date":106,"type":104},"2020-09-14",{"date":108,"type":86},"2025-12-31",{"name":5,"class":6},1]